title: Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics and oral bioavailability in human volunteers: a stable isotope study.
abstract: Dichloroacetic acid (DCAA) is a by-product of drinking water disinfection, is a known rodent hepatocarcinogen, and is also used therapeutically to treat a variety of metabolic disorders in humans. We measured DCAA bioavailability in 16 human volunteers (eight men, eight women) after simultaneous administration of oral and iv DCAA doses. Volunteers consumed DCAA-free bottled water for 2 weeks to wash out background effects of DCAA. Subsequently, each subject consumed (12)C-DCAA (2 mg/kg) dissolved in 500 ml water over a period of 3 min. Five minutes after the start of the (12)C-DCAA consumption, (13)C-labeled DCAA (0.3 mg/kg) was administered iv over 20 s and plasma (12)C/(13)C-DCAA concentrations measured at predetermined time points over 4 h. Volunteers subsequently consumed for 14 consecutive days DCAA 0.02 microg/kg/day dissolved in 500 ml water to simulate a low-level chronic DCAA intake. Afterward, the (12)C/(13)C-DCAA administrations were repeated. Study end points were calculation of AUC(0-->infinity), apparent volume of distribution (V(ss)), total body clearance (Cl(b)), plasma elimination half-life (t((1/2),beta)), oral absorption rate (K(a)), and oral bioavailability. Oral bioavailability was estimated from dose-adjusted AUC ratios and by using a compartmental pharmacokinetic model after simultaneous fitting of oral and iv DCAA concentration-time profiles. DCAA bioavailability had large interindividual variation, ranging from 27 to 100%. In the absence of prior DCAA intake, there were no significant differences (p > 0.05) in any pharmacokinetic parameters between male and female volunteers, although there was a trend that women absorbed DCAA more rapidly (increased K(a)), and cleared DCAA more slowly (decreased Cl(b)), than men. Only women were affected by previous 14-day DCAA exposure, which increased the AUC(0-->infinity) for both oral and iv DCAA doses (p < 0.04 and p < 0.014, respectively) with a corresponding decrease in the Cl(b).
authors.affiliation: Battelle Pacific NW Division, 1259 West Sequim Bay Road, Sequim, WA 98382, USA. ir_schultz@pnl.gov
authors.forename: Irvin R
authors.initials: IR
authors.lastname: Schultz
authors.forename: Robert E
authors.initials: RE
authors.lastname: Shangraw
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019540:Area Under Curve; D001682:Biological Availability; D002247:Carbon Isotopes; D003999:Dichloroacetic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D008297:Male; D014881:Water Supply
chemical_list: D002247:Carbon Isotopes; D003999:Dichloroacetic Acid